Stock listing
NASDAQ:TNYA Tenaya Therapeutics, Inc. Stock
Home listing (NASDAQ) of Tenaya Therapeutics, Inc.
Follow Tenaya Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:TNYA
$0.287 USD -0.020 (-6.6%)
Close on Nov 20, 2026
- Day range
- $0.283 – $0.321 USDNov 20, 2026
- Volume
- 4.34M sharesNov 20, 2026
- Market cap
- $65.32M USDAt the close on Nov 20, 2026 · price × 227.9M shares outstanding
- 52-week range
- $0.283 – $1.460 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $1.44M USDMedian day 2.28M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:TNYA · Home | $0.287 USD | -0.020 (-6.6%) | 4,341,674 | $0.290 | $0.321 | $0.283 | $0.307 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:TNYA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.287 | -0.020 | -6.6% | $0.290 | $0.321 | $0.283 | 4,341,674 | |
| $0.307 | -0.016 | -4.9% | $0.320 | $0.339 | $0.301 | 2,768,797 | |
| $0.323 | -0.011 | -3.2% | $0.330 | $0.340 | $0.311 | 5,467,712 | |
| $0.334 | -0.016 | -4.5% | $0.354 | $0.360 | $0.330 | 1,686,975 | |
| $0.349 | +0.002 | +0.5% | $0.350 | $0.358 | $0.334 | 1,304,557 | |
| $0.348 | -0.024 | -6.4% | $0.372 | $0.378 | $0.340 | 2,232,726 | |
| $0.371 | +0.001 | +0.2% | $0.380 | $0.398 | $0.370 | 1,039,054 | |
| $0.371 | -0.023 | -5.9% | $0.400 | $0.408 | $0.371 | 2,235,445 | |
| $0.394 | +0.034 | +9.4% | $0.374 | $0.410 | $0.367 | 2,946,477 | |
| $0.360 | +0.044 | +14.0% | $0.334 | $0.364 | $0.331 | 2,907,629 | |
| $0.316 | -0.054 | -14.6% | $0.385 | $0.386 | $0.300 | 7,583,380 | |
| $0.370 | +0.010 | +2.7% | $0.375 | $0.383 | $0.366 | 1,619,246 | |
| $0.360 | -0.001 | -0.2% | $0.358 | $0.378 | $0.351 | 1,661,173 | |
| $0.361 | -0.006 | -1.7% | $0.372 | $0.381 | $0.361 | 2,288,058 | |
| $0.367 | -0.031 | -7.8% | $0.394 | $0.400 | $0.366 | 2,657,548 | |
| $0.398 | -0.005 | -1.3% | $0.400 | $0.418 | $0.397 | 1,778,146 | |
| $0.404 | +0.002 | +0.6% | $0.410 | $0.415 | $0.400 | 1,207,851 | |
| $0.401 | -0.007 | -1.8% | $0.420 | $0.429 | $0.393 | 2,140,495 | |
| $0.409 | +0.020 | +5.0% | $0.392 | $0.419 | $0.385 | 3,439,964 | |
| $0.389 | +0.001 | +0.3% | $0.395 | $0.397 | $0.381 | 1,698,850 | |
| $0.388 | -0.002 | -0.6% | $0.395 | $0.408 | $0.386 | 1,721,179 | |
| $0.390 | -0.020 | -4.8% | $0.410 | $0.418 | $0.390 | 2,185,738 | |
| $0.410 | +0.032 | +8.6% | $0.381 | $0.419 | $0.380 | 3,263,258 | |
| $0.378 | -0.003 | -0.8% | $0.380 | $0.389 | $0.362 | 3,005,168 | |
| $0.381 | -0.028 | -6.8% | $0.410 | $0.417 | $0.370 | 6,836,062 | |
| $0.408 | +0.018 | +4.6% | $0.390 | $0.430 | $0.390 | 5,008,043 | |
| $0.391 | -0.131 | -25.0% | $0.500 | $0.510 | $0.360 | 18,145,480 | |
| $0.521 | -0.044 | -7.9% | $0.569 | $0.570 | $0.517 | 2,562,543 | |
| $0.566 | -0.015 | -2.6% | $0.562 | $0.577 | $0.545 | 2,514,683 | |
| $0.580 | +0.036 | +6.6% | $0.539 | $0.590 | $0.538 | 4,304,193 | |
| $0.544 | +0.011 | +2.0% | $0.530 | $0.547 | $0.521 | 3,637,379 | |
| $0.533 | -0.013 | -2.4% | $0.530 | $0.555 | $0.530 | 3,728,075 | |
| $0.547 | -0.018 | -3.1% | $0.570 | $0.577 | $0.542 | 2,703,448 | |
| $0.564 | 0.000 | 0.0% | $0.565 | $0.577 | $0.550 | 2,869,375 | |
| $0.564 | -0.002 | -0.3% | $0.570 | $0.580 | $0.561 | 3,725,994 | |
| $0.566 | -0.038 | -6.3% | $0.596 | $0.603 | $0.561 | 4,755,436 | |
| $0.604 | +0.011 | +1.8% | $0.612 | $0.625 | $0.600 | 1,814,762 | |
| $0.593 | +0.003 | +0.6% | $0.590 | $0.615 | $0.590 | 1,735,816 | |
| $0.590 | -0.020 | -3.2% | $0.600 | $0.608 | $0.570 | 6,083,975 | |
| $0.610 | -0.010 | -1.7% | $0.627 | $0.640 | $0.600 | 3,726,260 | |
| $0.620 | -0.041 | -6.2% | $0.660 | $0.670 | $0.620 | 3,594,213 | |
| $0.661 | -0.021 | -3.1% | $0.685 | $0.688 | $0.660 | 2,920,377 | |
| $0.682 | +0.008 | +1.2% | $0.674 | $0.700 | $0.674 | 1,226,633 | |
| $0.674 | -0.006 | -0.8% | $0.680 | $0.710 | $0.672 | 3,944,904 | |
| $0.679 | +0.007 | +1.1% | $0.680 | $0.710 | $0.669 | 4,873,201 | |
| $0.672 | +0.015 | +2.2% | $0.670 | $0.688 | $0.660 | 1,933,232 | |
| $0.658 | -0.013 | -1.9% | $0.662 | $0.674 | $0.650 | 1,942,552 | |
| $0.671 | -0.022 | -3.2% | $0.698 | $0.708 | $0.660 | 1,841,324 | |
| $0.693 | +0.053 | +8.3% | $0.656 | $0.709 | $0.650 | 3,081,623 | |
| $0.640 | -0.009 | -1.4% | $0.665 | $0.674 | $0.640 | 1,375,182 | |
| $0.649 | -0.012 | -1.8% | $0.662 | $0.670 | $0.640 | 2,283,533 | |
| $0.661 | -0.002 | -0.4% | $0.670 | $0.690 | $0.660 | 1,181,604 | |
| $0.663 | -0.020 | -2.9% | $0.685 | $0.710 | $0.661 | 2,365,328 | |
| $0.683 | -0.012 | -1.7% | $0.690 | $0.710 | $0.681 | 1,206,134 | |
| $0.695 | -0.004 | -0.6% | $0.699 | $0.710 | $0.691 | 1,555,103 | |
| $0.699 | +0.014 | +2.0% | $0.698 | $0.710 | $0.690 | 1,213,508 | |
| $0.685 | -0.002 | -0.3% | $0.693 | $0.700 | $0.682 | 1,080,718 | |
| $0.688 | -0.002 | -0.3% | $0.690 | $0.697 | $0.672 | 1,506,951 | |
| $0.690 | -0.005 | -0.7% | $0.701 | $0.704 | $0.687 | 1,112,529 | |
| $0.695 | -0.001 | -0.1% | $0.700 | $0.714 | $0.690 | 1,244,726 | |
| $0.696 | -0.005 | -0.7% | $0.694 | $0.715 | $0.690 | 935,931 | |
| $0.701 | +0.027 | +4.0% | $0.671 | $0.710 | $0.671 | 1,743,756 | |
| $0.675 | -0.023 | -3.2% | $0.697 | $0.700 | $0.657 | 4,029,676 | |
| $0.697 | +0.007 | +1.0% | $0.693 | $0.720 | $0.693 | 1,154,427 | |
| $0.691 | -0.022 | -3.1% | $0.713 | $0.727 | $0.691 | 1,528,737 |
- Ticker
- NASDAQ:TNYA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 4, 2026
Tenaya Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 34 slides
Latest news
Tenaya Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 4, 2026
Closed $0.316 (-14.6%) on Nov 5, 2026
Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
Sep 14, 2026
Closed $0.693 (+8.3%) on Sep 14, 2026
Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Aug 5, 2026
Closed $0.726 (-7.5%) on Aug 6, 2026
Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
Aug 4, 2026
Closed $0.785 (+5.8%) on Aug 5, 2026
Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer
Jun 29, 2026
Closed $0.735 (+2.4%) on Jun 29, 2026
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms
Jun 3, 2026
Closed $0.786 (-0.5%) on Jun 3, 2026
Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026
Jun 2, 2026
Closed $0.786 (-0.5%) on Jun 3, 2026
Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026
May 29, 2026
Closed $0.869 (+8.8%) on May 29, 2026
Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC
May 15, 2026
Closed $0.857 (-8.3%) on May 15, 2026
Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 6, 2026
Closed $0.79 (+4.8%) on May 6, 2026
Tenaya Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 20 in the last 12 months · 103 in all · newest Nov 4, 2026 · oldest 2021
- Decks
- 10 decks · latest September 2026
Where Tenaya Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:TNYA · Home listing · This page | NASDAQ | United States | USD |
| BOATS:TNYA | BOATS | United States | USD |
Valuation
EV/sales 0.5× against a median of 28.6×: the lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.38M USD
- P/E
- Loss
- EV/sales
- 0.5×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.2×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 2.42
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Tenaya Therapeutics, Inc. · NASDAQ:TNYA | US$65.32M | US$1.38M | n/a | 0.5× | n/a | 1.2× | n/a | 0.1× | 2.42 |
| Cingulate Inc. · NASDAQ:CING | US$67.48M | US$1.21B | n/a | n/a | n/a | 3.3× | n/a | 56.0× | 1.41 |
| Energenesis Biomedical Co., Ltd. · TWSE:6657 | US$67.22M | US$47.02M | n/a | 203× | n/a | 3.1× | n/a | 0.0× | n/a |
| MediciNova, Inc. · NASDAQ:MNOV | US$67.11M | US$38.45M | n/a | 41.1× | n/a | 1.6× | n/a | 0.0× | 0.56 |
| Dicot Pharma AB · OMXSTO:DICOT | US$66.56M | US$44.51M | n/a | n/a | n/a | 3.0× | n/a | 0.0× | n/a |
| Cardiff Oncology, Inc. · NASDAQ:CRDF | US$66.34M | US$32.82M | n/a | 58.7× | n/a | 2.4× | n/a | 0.0× | 1.32 |
| Polaryx Therapeutics, Inc. · NASDAQ:PLYX | US$66.30M | US$57.86M | n/a | n/a | n/a | 8.7× | n/a | 0.0× | 1.66 |
| PMV Pharmaceuticals, Inc. · NASDAQ:PMVP | US$66.17M | −US$36.25M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 1.43 |
| Gossamer Bio, Inc. · NASDAQ:GOSS | US$65.57M | US$55.23M | n/a | 0.7× | n/a | n/a | −159.5% | n/a | 1.56 |
| Atara Biotherapeutics, Inc. · NASDAQ:ATRA | US$64.49M | US$64.14M | n/a | 16.2× | n/a | n/a | −368.6% | n/a | 1.43 |
| AlzeCure Pharma AB · OMXSTO:ALZCUR | US$63.84M | US$62.72M | 21.3× | 6.6× | 25.6× | 7.1× | 31.6% | 0.0× | n/a |
| Median of the others | US$66.32M | US$51.12M | 21.3× | 28.6× | 25.6× | 3.0× | −159.5% | 0.0× | 1.43 |
Forecasts
4 strong buy · 2 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 3.67 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.44 · 3 analysts
- Revenue, year to Dec 2026
- 3.84M · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Faraz Ali | Chief Executive Officer |
| Eric Hyllengren | Chief Financial Officer |
| Jennifer Drimmer | General Counsel |
| Jay Vora | Senior Vice President, Portfolio and Program Management |
| Joanna Auch | Senior Vice President, People and Culture |
| Kathy Ivey | Senior Vice President, Research |
| Kee-Hong Kim | Chief Technology Officer |
| Whit Tingley | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| R. Sanders Williams | Chair of the Board |
| Amy Burroughs | Board Member |
| Catherine Stehman-Breen | Board Member |
| Deepak Srivastava | Board Member |
| Faraz Ali | Chief Executive Officer |
| Jeffrey T. Walsh | Board Member |
| June Lee | Board Member |
| Karah Parschauer | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · After close | −14.6% |
| Q2 2026 | Aug 5, 2026 · After close | −7.5% |
| Q1 2026 | May 6, 2026 · After close | +7.3% |
| Q4 2025 | Mar 24, 2026 | −3.9% |
| Q3 2025 | Nov 10, 2025 · Before open | +11.7% |
| Q2 2025 | Aug 6, 2025 · After close | −1.7% |
| Q1 2025 | May 7, 2025 · After close | −2.1% |
| Q4 2024 | Mar 10, 2025 | +18.7% |
| Q3 2024 | Nov 6, 2024 · After close | +12.1% |
| Q2 2024 | Aug 8, 2024 · After close | −1.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 14, 2024 · After close | −3.4% |
| Q4 2023 | Mar 18, 2024 · After close | −6.0% |
| Q3 2023 | Nov 8, 2023 · After close | −3.6% |
| Q2 2023 | Aug 9, 2023 · After close | +5.5% |
| Q1 2023 | May 10, 2023 · After close | +7.7% |
| Q4 2022 | Mar 8, 2023 · After close | −12.6% |
| Q3 2022 | Nov 10, 2022 · After close | +30.9% |
| Q2 2022 | Aug 10, 2022 · After close | −0.6% |
| Q1 2022 | May 11, 2022 · After close | +7.1% |
| Q4 2021 | Mar 23, 2022 · After close | +12.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 34 slides | September 2026 |
| Technical Presentation (June 2026) | Technical | 27 slides | Jun 3, 2026 |
| Jefferies Global Healthcare Conference 2026 | Conference | 41 slides | June 2026 |
| Technical Presentation (May 2026) | Technical | 30 slides | May 15, 2026 |
| ASGCT 2026 | Conference | 13 slides | May 15, 2026 |
| Technical Presentation (August 2025) | Technical | 30 slides | Aug 26, 2025 |
| Investor Presentation (April 2025) | Investor deck | 50 slides | April 2025 |
| Technical Presentation (2025) | Technical | 15 slides | 2025 |
| Technical Presentation (December 2024) | Technical | 28 slides | Dec 17, 2024 |
| Technical Presentation (2022) | Technical | 15 slides | 2022 |
Financings
| Raise | Date |
|---|---|
| Public offering of units and pre-funded units Announced: US$60M · US$1.2 a unit · Warrants at US$1.5 for 60 months · Leerink Partners +2 Dealers: Leerink Partners (co-lead), Piper Sandler (co-lead), LifeSci Capital Use of proceeds: Development of clinical and early-stage candidates, particularly TN-201 and TN-401, plus working capital and general corporate purposes | Dec 11, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$15.00 a share on Jul 29, 2021.
- Price
- US$15.00 a share
- Shares offered
- 12,000,000 shares of common stock
- Offering size
- US$180 million
- Underwriters' option
- Up to 1,800,000 more shares
- Underwriters
- Morgan Stanley, Cowen, Piper Sandler, Chardan · In the order on the cover
- Shares delivered
- On or about Aug 3, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 7, 2021 |
| Filed publicly | Jul 9, 2021 |
| Amended once | Jul 26, 2021 |
| Shares registered with an exchange | Jul 23, 2021 |
| Declared effective by the SEC | Jul 29, 2021 |
| Final prospectus, with the price | Jul 30, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jul 30, 2021 |
| EFFECT · Notice that a registration is effective | Jul 29, 2021 |
| S-1MEF · Registration of more shares for the same offering | Jul 29, 2021 |
| CERT · Exchange's certificate of listing | Jul 27, 2021 |
| CORRESP · Letter to the SEC | Jul 27, 2021 |
| CORRESP · Letter to the SEC | Jul 27, 2021 |
| CORRESP · Letter to the SEC | Jul 26, 2021 |
| S-1/A · Registration statement, amended | Jul 26, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Jul 23, 2021 |
| UPLOAD · Letter from the SEC | Jul 15, 2021 |
All 17 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Jul 9, 2021 |
| S-1 · Registration statement | Jul 9, 2021 |
| UPLOAD · Letter from the SEC | Jun 24, 2021 |
| DRS/A · Draft registration statement, amended | Jun 16, 2021 |
| DRSLTR · Letter to the SEC with a draft | Jun 15, 2021 |
| UPLOAD · Letter from the SEC | Jun 3, 2021 |
| DRS · Draft registration statement | May 7, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Jul 30, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 8.44M | 8.47M | 8.69M | 8.71M | 4.03M | 2.48M | 1.99M |
| Gross profit | -8.44M | -8.47M | -8.69M | -8.71M | -4.03M | -2.48M | -1.99M |
| Research and development | 68.6M | 86.7M | 98.0M | 94.5M | 54.4M | 31.1M | 23.1M |
| Selling, general and administrative | 24.7M | 29.2M | 33.2M | 31.1M | 18.4M | 7.81M | 4.56M |
| Operating income | -93.3M | -115.9M | -131.2M | -125.6M | -72.8M | -38.9M | -27.7M |
| Depreciation and amortization | 8.44M | 8.47M | 8.69M | 6.47M | 2.96M | 2.48M | 1.99M |
| EBITDA | -84.9M | -107.5M | -122.5M | -119.2M | -69.8M | -36.4M | -25.7M |
| Interest expense | 1.96K | 72.7M | 0 | 0 | |||
| Income before tax | -90.6M | -111.1M | -124.1M | -123.7M | -72.7M | -38.4M | -26.2M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | -453.0K |
| Net income | -90.6M | -111.1M | -124.1M | -123.7M | -72.7M | -38.4M | -25.8M |
| Earnings per share, basic | -0.59 | -1.31 | -1.68 | -2.76 | -4.10 | -39.50 | -0.95 |
| Earnings per share, diluted | -0.59 | -1.31 | -1.68 | -2.76 | -4.10 | -39.50 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 100.5M | 4.32M | 45.7M | 95.3M | 38.1M | 128.5M | 23.9M |
| Short-term investments | 0 | 57.1M | 59.0M | 91.3M | 213.2M | 0 | 2.75M |
| Receivables | 2.25M | ||||||
| Inventory | -19.9M | ||||||
| Current assets | 105.6M | 67.4M | 111.6M | 193.8M | 255.4M | 130.0M | 27.7M |
| Property, plant and equipment | 27.7M | 35.9M | 43.3M | 51.0M | 43.0M | 17.2M | 9.57M |
| Total assets | 146.9M | 119.9M | 170.5M | 278.9M | 314.2M | 148.2M | 38.0M |
| Accounts payable | 3.58M | 5.16M | 5.63M | 9.58M | 10.7M | 1.02M | 600.0K |
| Current liabilities | 15.4M | 16.0M | 22.7M | 24.2M | 21.8M | 5.04M | 4.12M |
| Total debt | 10.8M | 13.6M | 12.4M | 15.1M | 15.7M | ||
| Total liabilities | 23.7M | 27.1M | 31.1M | 35.6M | 35.7M | 8.72M | 81.7M |
| Shareholders' equity | 123.3M | 92.9M | 139.4M | 243.4M | 278.5M | -81.3M | -43.7M |
| Shares outstanding | 216.8M | 86.5M | 68.3M | 66.9M | 41.3M | 1.21M | 27.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -68.3M | -90.5M | -102.1M | -104.4M | -60.8M | -35.4M | -24.1M |
| Capital spending | -618.0K | -1.02M | -1.24M | -20.6M | -25.1M | -9.76M | -2.93M |
| Free cash flow | -68.9M | -91.5M | -103.3M | -125.1M | -85.9M | -45.2M | -27.0M |
| Cash from investing | 56.1M | 1.13M | 48.7M | 83.7M | -238.6M | -7.01M | -5.58M |
| Cash from financing | 108.4M | 47.7M | 4.05M | 77.8M | 209.0M | 147.3M | 30.5M |
| Share buybacks | 77.8M | -13.0K | -1.00K | -3.00K | |||
| Change in cash | 96.2M | -41.6M | -49.3M | 57.0M | -90.4M | 104.8M | 832.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2026 | Results | SEC |
| DEFA14A · Additional proxy material | Oct 23, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Oct 23, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Oct 13, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Sep 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 11, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Aug 24, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 17, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Aug 5, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2026 | Results | SEC |
| 3 · Initial statement of ownership | Jul 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 2, 2026 | Current report | SEC |
| 8-K · Current report | Jun 29, 2026 | Management or board change | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 8-K · Current report | May 29, 2026 | Management or board change | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 16, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 16, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 16, 2026 | Meeting notice | SEC |
| 10-K · Annual report | Mar 11, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 11, 2026 | Results | SEC |
| 8-K · Current report | Mar 5, 2026 | Material contract | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 26, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 25, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 25, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 20, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 20, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 17, 2026 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 12, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 10, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 10, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Feb 3, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 30, 2026 | Management or board change | SEC |
| 8-K · Current report | Jan 2, 2026 | Management or board change | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 17, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Dec 12, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Dec 12, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Dec 11, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 11, 2025 | Current report | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 10, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2025 | Results | SEC |
| 8-K · Current report | Nov 7, 2025 | Current report | SEC |
| UPLOAD · Letter from the SEC | Sep 10, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 4, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 26, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 18, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 31, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 16, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2025 | Insider trade | SEC |
| 8-K · Current report | May 30, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | May 7, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Apr 18, 2025 | Current report | SEC |
| ARS · Annual report to shareholders | Apr 17, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 17, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 17, 2025 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Apr 1, 2025 | Other filings | SEC |
| 8-K · Current report | Mar 28, 2025 | Current report | SEC |
| CORRESP · Letter to the SEC | Mar 27, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 26, 2025 | Other filings | SEC |
| S-3 · Registration statement | Mar 21, 2025 | Offer document | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 10, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 10, 2025 | Other filings | SEC |
| 10-K · Annual report | Mar 10, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 10, 2025 | Results | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 7, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 7, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 7, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 6, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Mar 4, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Mar 4, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Mar 3, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Mar 3, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 10, 2025 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Feb 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Feb 7, 2025 | Offer document | SEC |
| 8-K · Current report | Feb 7, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 28, 2025 | Management or board change | SEC |
| 8-K · Current report | Dec 17, 2024 | Current report | SEC |
| 8-K · Current report | Dec 17, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Nov 18, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2024 | Results | SEC |
| 4 · Change in ownership | Oct 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 21, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Sep 17, 2024 | Offer document | SEC |
| 8-K · Current report | Sep 16, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Aug 19, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 16, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 16, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 16, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| 8-K · Current report | Jul 25, 2024 | Management or board change | SEC |
| 8-K · Current report | Jun 27, 2024 | Management or board change | SEC |
| 8-K · Current report | May 31, 2024 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2024 | Results | SEC |
| ARS · Annual report to shareholders | Apr 17, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 17, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 17, 2024 | Meeting notice | SEC |
| 10-K · Annual report | Mar 18, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 18, 2024 | Results | SEC |
| 4 · Change in ownership | Mar 6, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 5, 2024 | Other filings | SEC |
| 4 · Change in ownership | Feb 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 20, 2024 | Other filings | SEC |
| 4 · Change in ownership | Feb 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 16, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 16, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 16, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 16, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| 424B5 · Prospectus | Feb 8, 2024 | Offer document | SEC |
| 8-K · Current report | Feb 8, 2024 | Material contract | SEC |
| S-8 · Registration statement for employee plans | Jan 31, 2024 | Offer document | SEC |
| SC 13G · Big-stake notice | Jan 31, 2024 | Big-stake notice | SEC |
This page holds 200 of 356 filings. Open Filings
Cap table
Built by 6ix from Tenaya Therapeutics, Inc.’s releases · as of Oct 29, 2026
- Common shares
- 227,928,240
- Fully diluted
- 227,928,240
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 227,928,240 | Oct 29, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 29, 2026 | 227,928,240 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Eli Casdin Other companies: GeneDx Holdings Corp. (Board Member · Since at least Apr 27, 2022); Standard BioTools Inc. (Director · Since at least Apr 4, 2022); 2Seventy Bio Inc (Director · Mar 20, 2024 – May 13, 2025 · Past); EQRx Inc (Director · Sep 30, 2022 – Sep 30, 2022 · Past); Century Therapeutics, Inc. (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Absci Corporation (Director · Jun 8, 2022 – Jun 8, 2022 · Past) | Director · Jun 10, 2022 – Nov 17, 2022 · Past |
| Leone Patterson Other companies: Kalaris Therapeutics, Inc. (Director · Since at least Apr 3, 2025); Zymeworks Inc. (EVP, Chief Bus & Fin Officer · Since at least Sep 1, 2024); Nkarta, Inc. (Director · Since at least Jun 8, 2022); Climb Bio, Inc. (Director · May 19, 2022 – May 19, 2022 · Past) | Chief Fin. and Bus. Officer · Feb 15, 2023 – Feb 23, 2024 · Past |
| Eric Hyllengren Other companies: Zura Bio Limited (Chief Financial Officer · Since at least Jul 1, 2025); Atara Biotherapeutics, Inc. (EVP, CFO and COO · Apr 1, 2023 – Mar 3, 2025 · Past) | Chief Financial Officer · Since at least Jun 29, 2026 |
| Karah Parschauer Other companies: Ultragenyx Pharmaceutical Inc. (EVP and Chief Legal Officer · Since at least Mar 1, 2024); Evolus, Inc. Common Stock (Director · Since at least Jan 30, 2024) | Board Member · Since at least Oct 18, 2024 |
| Amy Burroughs Other companies: Terns Pharmaceuticals, Inc. (Chief Executive Officer, Director · Since at least Feb 7, 2024) | Board Member · Since at least Oct 18, 2024 |
| Jeffrey T. Walsh Other companies: Bluebird bio Inc (Chief Strategy Officer · Mar 11, 2019 – Aug 20, 2019 · Past) | Board Member · Since at least Jul 29, 2021 |
| June Lee Other companies: Eledon Pharmaceuticals, Inc. (Director · Since at least Jan 10, 2025) | Board Member · Since at least Oct 18, 2024 |
| Catherine Stehman-Breen | Board Member · Since at least Nov 5, 2026 |
| Chihiro Saito | SVP, Accounting and Fin. Ops. · Aug 14, 2024 – Nov 18, 2024 · Past |
| Deepak Srivastava | Board Member · Since at least Nov 5, 2026 |
All 20 people
| Person | Seat |
|---|---|
| Faraz Ali | Chief Executive Officer · Since at least Sep 11, 2026 |
| Jay Vora | Senior Vice President, Portfolio and Program Management · Since at least Nov 4, 2026 |
| Jennifer Drimmer | General Counsel · Since at least Nov 4, 2026 |
| Joanna Auch | Senior Vice President, People and Culture · Since at least Nov 4, 2026 |
| Kathy Ivey | Senior Vice President, Research · Since at least Mar 9, 2026 |
| Kee-Hong Kim | Chief Technology Officer · Since at least Nov 4, 2026 |
| R. Sanders Williams | Chair of the Board · Since at least Nov 5, 2026 |
| Timothy Hoey | Chief Scientific Officer · Apr 26, 2022 – Mar 5, 2024 · Past |
| Tomohiro Higa | SVP, Finance · Since at least May 18, 2026 |
| Whit Tingley | Chief Medical Officer · Since at least Jun 3, 2026 |
Log in to ask 6ix AI your own questions about Tenaya Therapeutics, Inc.